From PR Newswire:
PITTSBURGH, Nov. 11 /PRNewswire/ -- Biocontrol Technology, Inc. (Nasdaq:
BICO) announced today that a meeting with high officials of the Food and Drug
Administration (FDA) regarding Biocontrol's recently submitted revised 510(k)
notification for its Diasensor 1000(TM) noninvasive glucose sensor for
diabetics took place last Wednesday, November 6, 1996.
A second meeting between the FDA and Biocontrol has been set for Wednesday,
November 13, 1996.
The Company further stated that the services of Mr. Jeff Nesbit, a former
FDA Associate Commissioner for Public Affairs, are being utilized to guide
Biocontrol through the FDA approval process and to assist with the overall
relationship between Biocontrol and the FDA.
Biocontrol Chief Executive Officer, Fred E. Cooper, stated, "Mr. Nesbit's
guidance and the overall cooperative attitude of the FDA are moving this
marketing approval process forward in a more timely fashion."
Biocontrol Technology, Inc. has its corporate offices in Pittsburgh, Pa. and
is involved in the development and manufacture of biomedical devices and
environmental products.
/CONTACT: Diane McQuaide, Investors, 412-429-0673, or fax: 412-279-9690,
or Susan Taylor, Media, 412-279-9466, or fax: 412-279-9447, both of Biocontrol
Technology, Inc./
08:01 EST |
